Post-transplantation Osteoporosis.
10.4285/jkstn.2011.25.4.239
- Author:
Yenna LEE
1
;
Chan Soo SHIN
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. csshin@snu.ac.kr
- Publication Type:Review
- Keywords:
Transplantation;
Osteoporosis;
Glucocorticoid;
Calcineurin inhibitor;
Cyclosporine;
Tacrolimus
- MeSH:
Cyclosporine;
Hematologic Diseases;
Humans;
Light;
Osteoporosis;
Quality of Life;
Risk Factors;
Survival Rate;
Tacrolimus;
Transplants
- From:The Journal of the Korean Society for Transplantation
2011;25(4):239-244
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Transplantation has become an established treatment in many end-stage organ diseases and hematologic diseases. The survival rate after transplantation has greatly improved due to the development of newer immunosuppressive drugs bringing the issues of post-transplantation complications to light. Osteoporosis and osteoporosis-related fragility fractures are feared complications, greatly influencing the quality of life in transplant patients. In addition to the conventional risk factors for osteoporosis, post-transplantation osteoporosis is caused by factors related to end-stage organ disease prior to transplantation and immunosuppressive therapy after transplantation. Since the rate of bone loss in post-transplantation osteoporosis is thought to be at the greatest immediately following transplantation, early measures need to be taken to prevent and treat post-transplantation osteoporosis. Both conventional and newer therapeutics for osteoporosis are largely being studied and used in practice for the prevention and treatment of post-transplantation osteoporosis.
